menu
    • menu
    [{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"North-Western State Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPP Pharmaclon Ltd. \/ North-Western State Medical University","highestDevelopmentStatusID":"7","companyTruncated":"SPP Pharmaclon Ltd. \/ North-Western State Medical University"},{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPP Pharmaclon Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SPP Pharmaclon Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ Biomerieux","highestDevelopmentStatusID":"10","companyTruncated":"Radboud University Medical Center \/ Biomerieux"},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Fox Chase Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fox Chase Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Fox Chase Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Cancer Center \/ Amgen Inc"},{"orgOrder":0,"company":"Ossium Health","sponsor":"Edwin Horwitz","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ossium Health \/ Edwin Horwitz","highestDevelopmentStatusID":"6","companyTruncated":"Ossium Health \/ Edwin Horwitz"}]

    Find Clinical Drug Pipeline Developments & Deals for Polyferon

    Menu

    Polyferon

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SPP Pharmaclon Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SPP Pharmaclon Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia

                            Details : Interferon Gamma is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Community-Acquired Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 27, 2022

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SPP Pharmaclon Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SPP Pharmaclon Ltd.

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : North-Western State Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis

                            Details : Interferon Gamma is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 04, 2021

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : North-Western State Medical University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ossium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ossium Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Edwin Horwitz

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

                            Details : Interferon Gamma is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 31, 2020

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Edwin Horwitz

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Moffitt Cancer Center

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Moffitt Cancer Center

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

                            Details : Interferon Gamma is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 13, 2017

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fox Chase Cancer Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fox Chase Cancer Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

                            Details : Interferon Gamma is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 25, 2015

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Radboud University Medical Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Radboud University Medical Center

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Biomerieux

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia

                            Details : Interferon Gamma is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Candidemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 05, 2011

                            Lead Product(s) : Polyferon

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Biomerieux

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth